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ith Clinical and Angiographic Outcomes After
lacement of Drug-Eluting Stents
etra Hoppmann, MD, Anna Erl, MD, Serin Türk, MD, Klaus Tiroch, MD,
ulinda Mehilli, MD, Albert Schömig, MD, Adnan Kastrati, MD, Werner Koch, PHD
unich, Germany
bjectives After novel ﬁndings from genomewide association studies that sequence variation on
hromosome 9p21.3 is a genetic factor for coronary heart disease, we investigated whether this lo-
us inﬂuenced the clinical and angiographic outcomes after implantation of drug-eluting stents in
oronary arteries.
ackground Recently, genomewide association studies have identiﬁed a locus on chromosome 9
approximately 100 kb in band p21.3) as the strongest genetic factor for coronary heart disease.
ethods We studied the rs7865618, rs1537378, rs1333040, and rs1333049 polymorphisms located
n chromosome 9p21.3 in a cohort of 2,028 patients who were treated with percutaneous coronary
ntervention and implantation of sirolimus- or paclitaxel-eluting stents. Records of 3-year adverse
linical outcomes were obtained from all stented patients. Follow-up angiography at 6 to 8 months
fter stenting was performed in 1,683 patients (83%).
esults The polymorphisms were not signiﬁcantly related with clinical outcomes at 3 years, includ-
ng death (p  0.18), myocardial infarction (p  0.19), repeat revascularization (p  0.08), and the
omposite end point of adverse events (death, myocardial infarction, repeat revascularization) (p 
.34). No association of the polymorphisms was found with angiographic measures at follow-up,
ncluding minimal lumen diameter (p  0.51), diameter stenosis (p  0.31), late lumen loss (p 
.05), and binary restenosis (p  0.31).
onclusions Speciﬁc polymorphisms in the chromosome 9p21.3 region that were shown to be as-
ociated with coronary heart disease in genomewide analyses were not related to the clinical and
ngiographic outcomes after the placement of drug-eluting stents in coronary arteries. (J Am Coll
ardiol Intv 2009;2:1149–55) © 2009 by the American College of Cardiology Foundation
rom the Deutsches Herzzentrum München and 1. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität
ünchen, Munich, Germany. The study was funded by an institutional grant from the Deutsches Herzzentrum München.anuscript received July 29, 2009; revised manuscript received August 13, 2009, accepted August 20, 2009.
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1150rug-eluting stents (DES) have become the treatment of
hoice for patients with symptomatic coronary artery disease
CAD) undergoing percutaneous coronary revasculariza-
ion. These stents combine the mechanical scaffolding
roperties of metallic stents with the site-specific delivery of
n antiproliferative agent designed to inhibit vascular re-
ponses to arterial injury, thereby reducing restenosis (1–5).
he 4- and 5-year data from randomized trials comparing
ES and bare-metal stents have shown rates of target vessel
evascularization to be reduced to one-half to two-thirds with
ES, such that the need for repeat intervention was10% to
5% for DES cohorts at long-term follow-up (6,7).
See page 1156
However, restenosis is far from being completely defeated
y current technology, and the question is whether genetic
lements are related to unfavorable clinical outcomes after
mplantation of DES. Genomewide analyses of single
ucleotide polymorphisms (SNPs) have recently identi-
ed a locus on chromosome 9 (100 kb in band p21.3)
as the as yet strongest genetic
factor for CAD and myocardial
infarction (MI) (8–11). Among
the sequence variations within
this region, the SNPs rs7865618,
rs1537378, rs1333040, and
rs1333049 were found to strongly
influence disease risk (8–16). For
example, the strength of the asso-
ciation between rs1333049 and
CAD was p  6.04  1010
(odds ratio: 1.24 per 1 risk allele
95% confidence interval: 1.20 to 1.29]), according to a result
f a meta-analysis that included 12,004 cases and 28,949
ontrols (14). As progression of coronary atherosclerosis and
ritical outcomes after stenting share common mechanisms,
ncluding inflammatory processes, we asked whether the same
SNPs were related to adverse clinical events and angiographic
estenosis after placement of DES in coronary arteries of
atients with CAD.
Table 1. Genotype Distributions and Minor Allele Fre
SNP* Position† Alleles M
rs7865618 22021005 AG 768 (
rs1537378 22051614 CT 832 (
rs1333040 22073404 TC 736 (
rs1333049 22115503 CG 526 (
Genotype values are n (%). *Single nucleotide polymorphism (SNP)
Information SNP database; †position of SNP on chromosome 9 accord
Het frequencyofheterozygouspatients;Maj frequencyofpatien
bbreviations
nd Acronyms
AD  coronary artery
isease
ES  drug-eluting stent(s)
I  myocardial infarction
NP  single nucleotide
olymorphism
LR  target lesion
evascularizationfor the minor allele.ethods
tudy population. The study included 2,028 patients with
schemic symptoms or evidence of myocardial ischemia in
he presence of 50% de novo stenosis located in native
oronary vessels. Patients were treated with percutaneous
oronary intervention and sirolimus- (Cypher, Cordis,
ohnson & Johnson Company, Warren, New Jersey) or
aclitaxel-eluting (Taxus, Boston Scientific, Natick, Massa-
husetts) stent implantation. An oral loading dose of 600
g of clopidogrel was administered to all patients at least
h before the intervention. During the procedure, patients
ere given intravenous aspirin, heparin, or bivaluridin;
lycoprotein IIb/IIIa inhibitor usage was at the discretion of
he operators. After the intervention, all patients received
00 mg/day aspirin indefinitely, 150 mg clopidogrel for the
rst 3 days (or until discharge) followed by 75 mg/day for at
east 6 months and other cardiac medications (including
eta-blockers, angiotensin-converting enzyme inhibitors,
tatins) according to the judgment of the patient’s physician.
fter stenting, patients remained in the hospital for at least
8 h. Re-hospitalization for repeat angiography was sched-
led between 6 and 8 months or earlier if noninvasive
valuation or clinical presentation suggested the presence of
schemia. Clinical follow-up by office visit or direct tele-
hone call to the patient was scheduled at 36 months. The
tudy protocol was approved by the institutional ethics
ommittee responsible for both participating centers,
eutsches Herzzentrum München and 1. Medizinische
linik, Klinikum rechts der Isar, Technische Universität
ünchen, Munich, Germany. All subjects gave their writ-
en, informed consent for participation in the study. The
eported investigations were in accordance with the princi-
les of the Declaration of Helsinki.
ata management, end points, and deﬁnitions. Relevant
ata were collected and entered into a computer database by
pecialized personnel of the participating clinics joint data
anagement center. Qualitative morphological lesion con-
itions were characterized by means of standard criteria
ies in the Study Cohort (n  2,028)
Genotype Distribution
Minor Allele
FrequencyHet Min
988 (48.7) 272 (13.4) 0.38
967 (47.7) 229 (11.3) 0.35
951 (46.9) 341 (16.8) 0.40
1018 (50.2) 484 (23.9) 0.49
cation number according to the National Center for Biotechnology
enome build 36.3.
ozygous for themajor allele;Min frequencyofpatientshomozygousquenc
aj
37.9)
41.0)
36.3)
25.9)
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115117). Baseline, post-procedural, and follow-up coronary
ngiograms were digitally recorded and assessed off-line in
he quantitative angiographic core laboratory (ISAR Cen-
er) with an automated edge-detection system (CMS ver-
ion 7.1; MEDIS Medical Imaging Systems, Leiden, the
etherlands) by 2 independent experienced operators. All
easurements were performed on cineangiograms recorded
fter the intracoronary administration of nitroglycerin using
he same single worst-view projection at all times. The
ontrast-filled nontapered catheter tip was used for calibra-
ion. Quantitative analysis was performed on both the
in-stent’ and ‘in-segment’ area (including the stented seg-
ent, as well as both 5-mm margins proximal and distal to
he stent). The primary end point of the study was the
omposite of all-cause death, MI, or need for target lesion
evascularization (TLR) over a period of 3 years. Diagnosis
f MI required the presence of new Q waves on the
lectrocardiogram and/or elevation of creatinine kinase or
ts MB isoform 3 the upper limit of normal in no fewer
han 2 blood samples. TLR was defined as any revascular-
zation procedure involving the target lesion due to luminal
enarrowing in the presence of symptoms or objective signs
f ischemia. Secondary end point was ‘in-segment’ binary
ngiographic restenosis, defined as diameter stenosis 50%
n the ‘in-segment’ area at follow-up angiography, regardless
f clinical symptoms. Stent thrombosis was classified as
efinite stent thrombosis according to recently agreed Ac-
demic Research Consortium criteria (18).
enetic analysis. TaqMan allelic discrimination assays
19,20) were designed and used for genotyping of
s7865618, rs1333040, and rs1333049 (pairwise r2  0.46),
hich were defined as lead SNPs in genomewide association
tudies (8–10), and rs1537378, the SNP with the strongest
ssociation with CAD in a fine mapping analysis (14). The
equences of oligonucleotide primers and TaqMan probes
re shown in Online Table 1. About 100 different polymer-
se chain reaction products obtained with each TaqMan
ystem were sequenced to test whether 1 or more additional
olymorphisms were present in the probe-binding section
f the amplicons, because they may interfere with TaqMan
eactions and result in wrong genotype assignments. The
elected SNPs were identified as the only sequence variabil-
ties in the probe-binding regions, which implicated that the
robability of genotyping errors because of possible further
equence variations was relatively low. In addition, the
enotype results obtained with sequence analyses and the
orresponding TaqMan reactions were in full agreement.
ith each SNP, retyping of 20% of the DNA samples was
one to control for correct sample handling and data
cquisition. Clinicians responsible for diagnosis and treat-
ent were not aware of the genetic data. All genetic
nalyses were blinded with regard to patient characteristics
nd study outcomes.Table 2. Baseline, Lesion, and Procedural Characteristics in the Groups
of Patients With and Without Adverse Clinical Events (Death, MI, TLR)
Within 3 Years After Stenting (n  2,028)
With Event
(n  444)
Without Event
(n  1,584) p Value
Age, yrs 68.5 10.5 65.6 10.4 0.0001
Women 99 (22.3) 344 (21.7) 0.79
Arterial hypertension 250 (56.3) 929 (58.6) 0.38
Hypercholesterolemia 304 (68.5) 1,126 (71.1) 0.29
Current smoking 58 (13.1) 240 (15.2) 0.27
Diabetes mellitus 145 (32.7) 411 (25.9) 0.005
Angina class 0.003
CCS I 123 (27.7) 498 (31.4)
CCS II 120 (27.0) 516 (32.6)
CCS III 99 (22.3) 305 (19.3)
CCS IV 102 (23.0) 265 (16.7)
Previous MI 186 (41.9) 547 (34.5) 0.004
Previous bypass surgery 72 (16.2) 146 (9.2) 0.0001
Multivessel disease 384 (86.5) 1,280 (80.8) 0.006
Left ventricular ejection fraction, % 52.2 14.2 55.4 12.4 0.0001
Target coronary vessel 0.37
LMCA 25 (5.6) 105 (6.6)
LAD 209 (47.1) 689 (43.5)
LCx 116 (26.1) 403 (25.4)
RCA 94 (21.2) 387 (24.4)
Lesion data
Lesion length, mm 13.4 7.8 13.6 7.4 0.59
Complex lesion 342 (77.0) 1,191 (75.2) 0.43
Restenotic lesion 137 (30.9) 396 (25.0) 0.01
Chronic occlusion 41 (9.2) 121 (7.6) 0.27
Before stenting
Reference diameter, mm 2.70 0.57 2.75 0.55 0.06
Minimal luminal diameter, mm 1.06 0.52 1.08 0.48 0.40
Diameter stenosis, % 61.1 15.9 60.9 14.7 0.88
Procedural data
Number of treated lesions 1.24 0.52 1.16 0.42 0.001
Measured balloon diameter, mm 3.09 0.57 3.13 0.55 0.15
Maximal balloon pressure, atm 14.7 3.0 14.5 2.9 0.06
Balloon-to-vessel ratio 1.16 0.12 1.15 0.12 0.14
Stented segment length per
lesion, mm
23.5 9.7 23.1 8.9 0.38
Number of stents per lesion 1.12 0.37 1.10 0.31 0.10
Drug-eluting stent type 0.04
Cypher stent 247 (55.6) 969 (61.2)
Taxus stent 197 (44.4) 615 (38.8)
Periprocedural abciximab
therapy
62 (14.0) 223 (14.1) 0.95
Immediately after stenting*
Minimal lumen diameter, mm 2.19 0.62 2.24 0.59 0.09
Diameter stenosis, % 23.4 12.5 22.8 12.1 0.37
Values aremean SDor n (%). *Minimal lumendiameter anddiameter stenosiswere determined
in the ‘in-segment’ area. Angina classes were defined according to the Canadian Cardiovascu-
lar Society (CCS) grading system. Complex lesions were defined as lesion types B2 and C
according to the American College of Cardiology/American Heart Association grading system.
LMCA left main coronary artery; LAD left anterior descending coronary artery; LCx left
circumflex coronary artery; MImyocardial infarction; RCA right coronary artery; TLR targetlesion revascularization.
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1152tatistical analysis. The analysis consisted of a comparison
f baseline, lesion, procedural, and post-procedural charac-
eristics between the group of patients who experienced the
ccurrence of adverse clinical events (primary study end
oint) and the group without events. Patient characteristics
ere also compared between the group of patients with
inary angiographic restenosis (secondary study end point)
nd the group without restenosis. Discrete variables were
ssessed with the use of the chi-square test. Continuous
ariables are expressed as mean  SD and were compared
y means of the unpaired 2-sided t test. In the end point
nalyses, additive genetic models were used, and the p values
re reported from trend tests based on the number of variant
lleles in each SNP. A Cox proportional hazards model for
he composite end point of adverse clinical events and a
ultivariable logistic regression model of angiographic re-
tenosis were applied to adjust for potentially confounding
ffects of baseline and lesion-related characteristics. All
tatistical analyses were performed using S-Plus software
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Figure 1. Kaplan-Meier Estimates for 3-Year Adverse Event Rates
Kaplan-Meier curves are shown for combined adverse event rates related to (A
period. Curves in purple are for the patients homozygous for the major alleles
the patients homozygous for the minor alleles of the respective single nucleotTIBCO Software Inc., Palo Alto, California). desults
enotype distributions and minor allele frequencies. The
enotypes related to rs7865618, rs1537378, rs1333040, and
s1333049 were determined in the patients (n 2,028), and
heir distributions and the minor allele frequencies are
hown in Table 1. Similar genotype distributions and minor
llele frequencies were observed in the cohort with symp-
omatic CAD assessed here and patient groups with CAD
xamined in prior studies with participants of European
ncestry from Germany, Iceland, the United Kingdom, and
he U.S. (Online Table 2).
linical outcome. Three-year follow-up was complete for
he study cohort. The composite of all-cause death, MI, or
eed for TLR, the primary end point of the study, was
bserved in 444 patients (21.9%). Baseline, lesion-related,
nd procedural parameters at the time of intervention in the
roups with and without adverse clinical events are shown in
able 2. The incidences of stent thrombosis (n 24; 1.2%),
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11531.9%), and the combined incidence of death, MI, and
LR were not associated with the SNPs in additive genetic
odels (Online Table 3). Kaplan-Meier curves illustrate the
ack of relationship between each of the SNPs and com-
ined adverse event rates (Fig. 1). After adjustments were
ade for all baseline and lesion-related characteristics
hown in Table 2, no SNP was found to exert a significant
ndependent influence on the composite end point of
dverse events in a Cox proportional hazards model (p 
.07).
ngiographic results. Follow-up coronary angiography at 6
o 8 months was performed in 1,683 patients (83%).
ngiographic restenosis (diameter stenosis 50% in the
in-segment’ area), the secondary end point, was observed in
27 patients (13.5%). Table 3 shows baseline, lesion-
elated, and procedural parameters at the time of interven-
ion in the group of patients with restenosis and the group
ithout restenosis. Minimal lumen diameter (‘in segment’),
iameter stenosis (‘in segment’), late lumen loss (‘in stent’),
nd incidence of binary restenosis at follow-up were not
ignificantly associated with the SNPs in additive genetic
odels (Online Table 4). After adjusting for all baseline
nd lesion-related variables displayed in Table 3, no asso-
iation of the SNPs with angiographic binary restenosis
as observed in a multivariable logistic regression model
p  0.08).
iscussion
ssociation with CAD and MI was shown for multiple
NPs across a region of approximately 100 kb on chromo-
ome 9 (band p21.3), including rs7865618, rs1537378,
s1333040, and rs1333049 (8–16). Significantly increased
isease risks were attributed to rs7865618-A, rs1537378-C,
s1333040-T, and rs1333049-C, the major alleles of these
NPs (8–16). We assessed the association of the same 4
AD- and MI-related SNPs with clinical and angiographic
utcomes after the placement of DES in coronary arteries of
atients with symptomatic CAD. In essence, the results of
he study provided no evidence for a relationship of the
NPs with adverse clinical events or angiographic measures
f restenosis. The sample size provided the analysis with
0% power to detect increases of 20% of composite adverse
vents and 33% of angiographic restenosis in the carriers of
he putative risk alleles (2-sided alpha-level of 0.01).
Using 4 SNPs of the chromosome 9p21.3 region that
ere different from those employed here, association with
linical outcomes after interventions in patients with angio-
raphically documented CAD was examined previously
21). These SNPs, rs2383206, rs2383207, rs10757274, and
s10757278, are all in relatively tight pairwise linkage
isequilibrium among each other (0.84 r2 0.96) (21), as
ompared with the much wider genetic variation covered byTable 3. Baseline, Lesion, and Procedural Characteristics in Patients
With and Without Angiographic Restenosis (n  1,683)
With
Restenosis
(n  227)
Without
Restenosis
(n  1,456) p Value
Age, yrs 67.0 10.7 65.5 10.4 0.05
Women 58 (25.6) 293 (20.1) 0.06
Arterial hypertension 143 (63.0) 832 (57.1) 0.10
Hypercholesterolemia 166 (73.1) 1,047 (71.9) 0.70
Current smoking 31 (13.7) 213 (14.6) 0.70
Diabetes mellitus 62 (27.3) 370 (25.4) 0.54
Angina class 0.94
CCS I 69 (30.4) 466 (32.0)
CCS II 72 (31.7) 453 (31.1)
CCS III 48 (21.1) 288 (19.8)
CCS IV 38 (16.7) 249 (17.1)
Previous myocardial infarction 91 (40.1) 516 (35.4) 0.17
Previous bypass surgery 40 (17.6) 144 (9.9) 0.0005
Multivessel disease 193 (85.0) 1,180 (81.0) 0.15
Left ventricular ejection fraction, % 53.3 13.7 55.3 12.3 0.02
Target coronary vessel 0.38
LMCA 9 (4.0) 99 (6.8)
LAD 99 (43.6) 632 (43.4)
LCx 59 (26.0) 381 (26.2)
RCA 60 (26.4) 344 (23.6)
Lesion data
Lesion length, mm 14.3 8.6 13.2 7.2 0.04
Complex lesion 188 (82.8) 1,078 (74.0) 0.004
Restenotic lesion 79 (34.8) 380 (26.1) 0.006
Chronic occlusion 31 (13.7) 102 (7.0) 0.0006
Before stenting
Reference diameter, mm 2.61 0.47 2.76 0.57 0.0001
Minimal lumen diameter, mm 0.96 0.47 1.09 0.49 0.0003
Diameter stenosis, % 63.3 16.1 60.7 14.8 0.02
Procedural data
Number of treated lesions 1.33 0.64 1.16 0.40 0.0001
Measured balloon diameter, mm 3.01 0.49 3.14 0.57 0.002
Maximal balloon pressure, atm 15.1 3.20 14.4 2.81 0.002
Balloon-to-vessel ratio 1.16 0.11 1.15 0.12 0.04
Stented segment length per
lesion, mm
24.9 9.8 22.8 8.9 0.001
Number of stents per lesion 1.15 0.39 1.09 0.30 0.008
Drug-eluting stent type 0.03
Cypher stent 122 (53.7) 894 (61.4)
Taxus stent 105 (46.3) 562 (38.6)
Periprocedural abciximab therapy 25 (11.0) 209 (14.4) 0.18
Immediately after stenting*
Minimal lumen diameter, mm 2.05 0.58 2.26 0.59 0.0001
Diameter stenosis, % 26.0 13.6 22.5 11.8 0.0001
Values aremean SDor n (%). *Minimal lumendiameter anddiameter stenosiswere determined
in the ‘in-segment’ area. Angina classes were defined according to the CCS grading system.
Complex lesions were defined as lesion types B2 and C according to the American College of
Cardiology/American Heart Association grading system.
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1154he SNPs used in the current study (0.21  r2  0.81), and
re also tightly linked to rs1333049 (0.81  r2  0.97).
orresponding to the present results, the SNPs, which
howed strong associations with CAD and MI in genome-
ide approaches (8–11), were not associated with incident
I or death during longitudinal follow-up in the prior
tudy (21). The results of the present study are also in accord
ith recent data showing no association between
s2383206, rs2383207, rs10757278, and rs1333049 and the
everity and progression of coronary atherosclerosis in pa-
ients with CAD (22).
The polymer-regulated, site-specific delivery of agents,
uch as sirolimus and paclitaxel, from DES were shown to
nhibit tissue growth after coronary stent implantation
ompared with bare-metal stents (2,3). Likely due to de-
ayed and incomplete endothelialization (23,24), the inci-
ence of stent thrombosis, especially after the first year of
mplantation, is increased with these DES compared with
heir bare-metal counterparts (7,25). It was not possible to
ddress a potential association of the SNPs with stent
hrombosis in the present cohort, because the study was
nderpowered for this relatively uncommon complication.
Genotype distributions and allele frequencies in the
ohort were typical of samples with CAD, as demonstrated
y a comparison with data from prior studies (Online Table
). The present findings suggest that the CAD-associated
NPs are not related with adverse processes that may ensue
rom stenting in coronary arteries, most prominently throm-
osis culminating in MI and neointima formation leading to
estenosis. Associations of SNPs on chromosome 9p21.3
ith cardiovascular disease, as reported from genomewide
tudies and subsequent replications using identified SNPs or
heir neighbor SNPs (8–16), may reflect an influence on the
evelopment and progression of coronary atherosclerosis in
ative arteries. Higher prevalences of the risk alleles in case
CDKN2A CDKN2B
22025k22000k21975k21950k
rs7865618
p15AS
Figure 2. Genes Close to or Overlapping With a Region on Chromosome 9p
A 100 kb region on chromosome 9p21.3 containing multiple single nucleotid
marked with stripes. The positions of the polymorphisms, rs7865618, rs153737
entations (directions of transcription) of genes near and within this sequence
gene encoding the cyclin-dependent kinase inhibitors p16INK4a and p14ARF; CD
for antisense noncoding RNA in the INK4 locus; p15AS, antisense RNA directedroups with MI than in control groups (10–12,14,16) may 9e related to ongoing atherosclerosis in these patients rather
han critical complications of the disease resulting in MI,
uch as rupture of vulnerable plaques and thrombosis.
upportive evidence for this possibility came from observa-
ions involving rs1333049 or rs2891168, a SNP in strong
inkage disequilibrium with rs1333049, showing that asso-
iated risks in CAD patients with MI were not higher but
ather somewhat lower than in CAD patients without MI
12,14).
The pathomechanism underlying the association of chro-
osome 9p21.3 SNPs with CAD is not known. Two genes,
DKN2A, encoding p16INK4a and p14ARF, and CDKN2B,
ncoding p15INK4b (26,27), are located at some distance
rom the SNPs most closely related with CAD (Fig. 2).
16INK4a, p14ARF, and p15INK4b are critical inhibitors of
athways involved in the regulation of cell proliferation,
ging, senescence, and apoptosis (28,29), which are impor-
ant features of atherosclerosis. Many of the SNPs showing
he strongest association with CAD map within a gene,
ermed ANRIL (Antisense Non-coding RNA in the INK4
ocus), spanning a region of 126.3 kb and specifying
oncoding RNA products of unknown function (Fig. 2)
12,30). ANRIL is expressed in vascular endothelial cells,
onocyte-derived macrophages, coronary smooth muscle cells,
nd atheromatous human vessels, and evidence for a coordi-
ated transcriptional regulation of ANRIL, CDKN2A, and
DKN2B has been obtained (12,30). The 5’ portion of ANRIL
ives rise to a natural antisense RNA of 34.8 kb, named p15AS
NA, that was shown to specifically interfere with transcrip-
ion of p15INK4b (sense) RNA from CDKN2B in tumor cells
Fig. 2) (31). It remains to be determined whether gene
ilencing or some other mechanism involving CDKN2A,
DKN2B, and antisense RNA can explain the well-
ocumented association between SNPs in the chromosome
22125k22100k22075k22050k
rs1537378 rs1333040 rs1333049
ANRIL
Associated With Coronary Heart Disease
ymorphisms strongly associated with coronary heart disease (8–16) is
333040, and rs1333049, addressed in this report are indicated. Loci and ori-
tentially involved in disease mechanisms are shown as arrows. CDKN2A,
gene encoding the cyclin-dependent kinase inhibitor p15INK4b; ANRIL, gene
st the (sense) RNA for p15INK4b.21.3
e pol
8, rs1
and po
KN2B,p21.3 region and CAD (12,30–32).
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o support was obtained for associations of specific CAD-
elated SNPs on chromosome 9p21.3 with adverse clinical
vents and angiographic results after placement of DES in
oronary arteries.
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